GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science

Novo Nordisk has sued Eli Lilly, alleging its Zepbound advertisements misleadingly compare low doses of Novo's Wegovy to Zepbound's highest dose, cherry-picking outdated clinical trial data to claim superiority. Eli Lilly defends its ads as based on the only head-to-head trial and states it discloses the dose comparison limitation.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.